ALK acquires drug against swimmer's ear from now former US partner

Allergy firm ALK is now the sole owner of a drug against swimmer's ear after the company offered an undisclosed sum to US biotech and pharmaceutical Otonomy, which developed the drug and until now was in a partnership with ALK since June last year.

Carsten Hellmann, CEO of ALK | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

Allergy company ALK is now the exclusive owner of the FDA-approved drug Otiprio, used for treating acute otitis media, also known as swimmer's ear, of which there are more than 4 million cases annually in the US spread out among 3.4 million patients.

CEO of ALK Carsten Hellmann confirms the news in the recently published quarterly report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs